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Aims Mesenchymal stem cells (MSCs) can ameliorate myocardial infarction (MI) injury. However, older-donor MSCs seem
less efficacious than those from younger donors, and the contributing underlying mechanisms remain unknown. Here,
we determine how age-related expression of pigment epithelium-derived factor (PEDF) affects MSC therapeutic effi-
cacy for MI.
Methods
and results
Reverse transcriptase–polymerized chain reaction and enzyme-linked immunosorbent assay analyses revealed dra-
matically increased PEDF expression in MSCs from old mice compared to young mice. Morphological and functional
experiments demonstrated significantly impaired old MSC therapeutic efficacy compared with young MSCs in treat-
ment of mice subjected to MI. Immunofluorescent staining demonstrated that administration of old MSCs compared
with young MSCs resulted in an infarct region containing fewer endothelial cells, vascular smooth muscle cells, and
macrophages, but more fibroblasts. Pigment epithelium-derived factor overexpression in young MSCs impaired the
beneficial effects against MI injury, and induced cellular profile changes in the infarct region similar to administration of
old MSCs. Knocking down PEDF expression in old MSCs improved MSC therapeutic efficacy, and induced a cellular
profile similar to young MSCs administration. Studies in vitro showed that PEDF secreted by MSCs regulated the pro-
liferation and migration of cardiac fibroblasts.
Conclusions This is the first evidence that paracrine factor PEDF plays critical role in the regulatory effects of MSCs against MI
injury. Furthermore, the impaired therapeutic ability of aged MSCs is predominantly caused by increased PEDF
secretion. These findings indicate PEDF as a promising novel genetic modification target for improving aged MSC
therapeutic efficacy.
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Introduction
Myocardial infarction (MI) remains the most common cause of
cardiac morbidity and mortality in the developed world. Acute myo-
cardial ischaemia causes rapid death of cardiomyocytes and vascula-
ture, leading to left ventricular (LV) remodelling, including
progressive fibrotic myocardium replacement, LV dilation, and
heart failure.1 In the last decade, stem cell therapy has been shown
to be a promising method for treating MI,2 and mesenchymal stem
cells (MSCs) have been considered a good option because of their
unique biological attributes.3,4 When introduced to an infarcted
heart, MSCs prevent deleterious remodelling and improve recov-
ery.3,4 Increasing evidence demonstrates that the beneficial effect
of MSCs is significantly mediated through incompletely understood
indirect paracrine actions,4– 8 supplying multiple therapeutic
growth factors and cytokines regulatory of the ongoing MI pathologi-
cal processes.4– 6 In recent studies, pigment epithelium-derived
factor (PEDF), a member of the serpin protease inhibitor family
lacking protease inhibitory activity, was identified as a major
MSC-secreted protein.9,10 Pigment epithelium-derived factor is a
multifunctional, pleiotropic protein with antiangiogenic, anti-
oxidant, anti-inflammatory, anti-tumourigenic, and neuroprotective
properties, with cell-type-dependent biological function.11 Thus,
PEDF might be contributive to MSC paracrine actions regulating
ongoing MI pathologic processes, but has not been investigated.
Most clinical studies have used autologous stem cells for MI
treatment. Patients suffering MI typically are of advanced age.
However, the impact of donor age on MSCs therapeutic efficacy
remains uncertain.12 Clarification of this issue and underlying
mechanisms are of utmost importance, as their elucidation will
give insight regarding MSC genetic modification with age and any
potential reversibility. In the present study, MSCs from older
mice secreted significantly greater PEDF levels compared to
young mice. We hypothesized that PEDF plays a critical role in
MSC paracrine functioning during the pathological processes
associated with MI. Furthermore, age-related PEDF expression
may critically influence MSC therapeutic efficacy in MI treatment.
Methods
Detailed methodology is available in the Online Data Supplement.
Laboratory animals, isolation, culture, and
characterization of mesenchymal stem cells
All experimental animal procedures were approved by the Animal
Experiment Administration Committee of our institution. Mesenchy-
mal stem cells were isolated and expanded from young (8-week-old)
and older (18-month-old) male C57BL/6 mice via standard proto-
cols.13 Third-passage cells were used for experiments. To validate
the enriched MSCs population, flow cytometry characterized the
surface antigens, and in vitro differentiation of cultured MSCs was per-
formed as previously reported.13
Detection of pigment epithelium-derived
factor expression in vitro
Reverse transcriptase–polymerized chain reaction (RT–PCR) analysis
was performed as previously described.9 Pigment epithelium-derived
factor concentrations released by MSCs were measured via mouse
PEDF enzyme-linked immuno sorbent assay (ELISA) kit (USCN Life.
Science & Technology Company, Double Lake, MO, USA) per manu-
facturer’s instructions.
Adenoviral vectors and mesenchymal stem
cells transduction
Briefly, human type 5 adenoviral vectors (SinoGenoMax Co., Ltd, Beijing,
China) expressing human-PEDF (Ad.PEDF) from a cytomegalovirus
(CMV) immediate early promoter were generated, and the E1 and E3
regions of the viral genome were replaced with a reporter gene
[green fluorescent protein (GFP)]. Control vectors (Ad.Null) not expres-
sing PEDF were constructed and produced concomitantly. In addition,
the Ad.shPEDF vector, in which a shRNA was driven by the U6 promoter,
and GFP was driven by an independent CMV promoter, which resulted
in dramatically attenuated PEDF levels, was generated for further exper-
iments. Ad.shctrl (Ad-Scramble) vector served as a control.
Mesenchymal stem cells were incubated with adenoviruses at infec-
tion multiplicity of 3000 for 2 h. Transduction efficiency was analysed
24 h after transduction by flow cytometry and inverted microscopy.
Model of myocardial infarction and
mesenchymal stem cells transplantation
Myocardial infarction was established as described previously.14 Briefly,
8-week-old male C57BL/6 mice (under general anesthaesia, with 2%
isoflurane) were subjected to small left thoracotomy, temporary
cardio-exteriorization, and placement of 6.0 silk suture below origin
of the left anterior descending coronary artery (LAD). The heart
was replaced immediately into the thoracic cavity, with thoracic air
evacuation to avoid pneumothorax. 4.0 × 106 MSCs/mouse were tail-
vein injected 0.5–1 h post-MI. Control animals underwent LAD
ligation with only saline injection.
Detection of mesenchymal stem cells
recruitment and pigment epithelium-derived
factor expression in vivo
To investigate MSC recruitment, alternate sets of 8 mm-thick serial
vertical sections of the infarcted heart were mounted on gelatin-
coated slides for fluorescent microscope examination, and images
were analysed by Image-Pro Plus, Media Cybernetics Inc., Carlsbad,
CA, USA. Infarct region PEDF expression was identified by immuno-
fluorescence. Sections were sequentially incubated with goat anti-
human PEDF primary antibodies (R&D Systems, Minneapolis, MN,
USA) or rat anti-mouse PEDF primary antibodies (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) and Texas Red-conjugated
secondary antibody. Furthermore, PEDF levels were also determined
by a human or mouse PEDF ELISA kit (USCN Life. Science & Technol-
ogy Company).
Analysis of cellular profile in the MI area
On Day 7 post-MI, hearts were fixed and sectioned. Slides were incu-
bated with primary antibodies for CD31 (Chemicon, Temecula, CA,
USA), aSMA (Neomarkers, Fremont, CA, USA), vimentin (Abcam,
Cambridge, MA, USA), Cardiac Troponin I (Abcam, Raleigh, NC,
USA), and F4/80 (Serotec, Raleigh, NC, USA). After PBS rinsing,
slides were incubated overnight with biotinylated goat anti-mouse
IgG (Sigma-Aldrich, St. Louis, MO, USA) or donkey anti-rat IgG
antibodies (Jackson, West Grove, PA, USA), further incubated with
Texas red-conjugated streptavidin in PBS. Cell nuclei were stained
with 4′ , 6′-diamino-2-phenylindole (DAPI; Molecular Probes, Eugene,
OR, USA).
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Measurement of left ventricular fibrosis
and left ventricular function
Left ventricle cross sections (4 mm thick) at the mid-papillary muscle
level were Trichrome-Masson stained. For LV functional analysis,
mice were anesthaetized by intraperitoneal 1% sodium pentobarbital
injection (50 mg/kg body weight) before a micro-catheter was inserted
into the LV via the right carotid artery. Left ventricular function and
electrocardiogram data were recorded using a Biopac Data Acquisition
System (Biopac Systems Inc., Goleta, CA, USA).
Co-culture of cardiac fibroblasts with
mesenchymal stem cells for proliferation
and migration assays
Young MSCs, old MSCs, Y&Ad.Null, Y&Ad.PEDF, O&Ad.shctrl, or
O&Ad.shPEDF cells were plated (1.5 × 105 cells/cm2) in a transwell
insert (Millipore, Billerica, MA, USA) with 0.4 mm pores, while neo-
natal mouse cardiac fibroblasts (CFs) were plated as control. The
insert was then placed into 24-well plates, where CFs were plated
(2 × 105 cells/cm2). Cardiac fibroblast proliferation was evaluated
48 h after co-culture under hypoxia using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cardiac fibroblast
migration assay was carried out using a transwell insert of 8 mm
pore size. Chemotaxis was induced by MSCs in the lower compart-
ment. Cardiac fibroblasts were serum-starved overnight, and 5 × 104
cells were seeded in the upper compartment. Cells were allowed to
migrate for 8 h under hypoxic conditions. The filters were stained
with crystal violet for microscopy. A blinded, single person counted
the number of cells that migrated to the lower filter surface.
The direct effects of pigment
epithelium-derived factor on cardiac
fibroblasts
Cardiac fibroblasts were stimulated for 8 h with 0–200 ng/mL recom-
binant human (rh) PEDF (Peprotech Inc., Rocky Hill, NJ, USA) under
hypoxia, and the MTT assay was performed. Cell cycle distribution
was detected by a Calibur flow cytometer (Becton–Dickinson, San
Jose, CA, USA). For western blotting analysis, 50 mg total proteins
from each cell extract was resolved with sodium dodecyl sulfate–poly-
acrilamide gel electrophoresis and transferred onto a polyvinylidence
difluoride membrane (Immobillon-P; Millipore). The membrane was
then incubated sequentially with primary anti-cyclin D1, anti-p27, or
anti-glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotech-
nology, Inc.) and horseradish peroxidase-conjugated secondary anti-
bodies; bands were detected with enhanced chemiluminescence
(Pierce, Rockford, IL, USA). The CF migration assay was carried out
using a transwell insert as described above, except that rh-PEDF was
used for chemotaxis in the lower compartment. AnnexinV-FITC apop-
tosis detection kit (Beckman Coulter, Fullerton, CA, USA) determined
apoptotic cell percentage, and flow cytometry analysis (BD Bio-
sciences, San Diego, CA, USA) was performed. Moreover, CFs were
stained with Hoechst 33258. Apoptotic CFs were identified on the
basis of their nuclear morphology (presence of condensed chromatin
and fragmentation). The nuclei from five random fields were counted
by a single blinded person, and the percentage of apoptotic nuclei rela-
tive to total nuclei was calculated.
Statistical analyses
Data were expressed as mean+ standard error of the mean (SEM).
Multiple group comparisons were evaluated via one-way analysis of
variance followed by least significant difference -t-test for post hoc
analysis. Comparisons between two independent groups were ana-
lysed using the Student t-test. Analyses were performed using SPSS
software, Chicago, IL, USA. P values less than 0.05 were considered
to be statistically significant and tests were performed two sided.
Results
Mesenchymal stem cells from older
donors express and secrete more
pigment epithelium-derived factor
than younger donors
After three passages, MSC pluripotency was confirmed by capacity
to differentiate into adipogenic and osteogenic lineages in vitro
(Figure 1A). By flow cytometry analysis, cultured MSCs expressed
CD29, CD44, CD73, CD90, and CD105, and were devoid of haema-
topoietic markers CD11b, CD34, and CD45 (Supplementary
material online, Table S1). Notably, RT–PCR (Figure 1B) and ELISA
(Figure 1C) revealed that, in comparison to young MSCs, significantly
greater PEDF expression (for both mRNA and protein levels) was
found in older MSCs under both normoxic and hypoxic conditions.
Adenoviral vector-transduced
mesenchymal stem cells recruit to the
infarct region, and regulate pigment
epithelium-derived factor levels
We used adenoviral vectors carrying human-PEDF and or short
hairpin RNA (shRNA) targeting mouse-PEDF to overexpress PEDF
in young MSCs or knock down PEDF expression in older MSCs
respectively. All adenoviral vectors were designed to carry a GFP
reporter. The transduction efficiency of these adenoviral vectors
was analysed (Supplemental Results). Utilizing our mouse MI model,
we intravenously injected either: (i) saline, (ii) young MSCs, (iii) old
MSCs, (iv) Y&Ad.Null, (v) Y&Ad.PEDF, (vi) O&Ad.shctrl, or (vii)
O&Ad.shPEDF. On Day 1 after MI, a large number of GFP positive
cells were found dispersed in the infarct region (Figure 2A and B). Fur-
thermore, no significant differences were observed in the green fluor-
escent intensity of infarcted hearts among Y&Ad.Null, Y&Ad.PEDF,
O&Ad.shctrl, and O&Ad.shPEDF groups (Figure 2C), indicating similar
numbers of MSCs dispersal in the infarct region among these
groups. Subsequently, we performed immunofluorescent staining
and ELISA to identify the ability of genetically modified MSCs in the
infarct region to regulate local PEDF levels. Greater PEDF levels
were found in the infarct region after administration of MSCs of
older compared to young origin. Adenoviral vectors were used to
overexpress human-PEDF or block mouse-PEDF expression in
young or old MSCs in vivo, respectively, thereby leading to PEDF
level significantly changes in the infarct region (Supplemental Results).
Decreased efficacy of old mesenchymal
stem cells for myocardial infarction
treatment is associated with increased
pigment epithelium-derived
factor expression
In order to study whether different PEDF levels could affect the
efficacy of MSCs for MI, we performed gross cardiac morphology
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and function analyses. As illustrated in Figure 3A, compared to
saline treatment, both young and old MSCs significantly attenu-
ated fibrosis post-MI, but to greater extent after young MSC
treatment. Compared to saline treatment, administration of
young MSCs after MI markedly improved LV functional
parameters. Compared to young MSC treatment, administration
of old MSCs after MI increased the ratio of the pre-ejection
period/left ventricular ejection time (Figure 3B) and LV end-
diastolic pressure (Figure 3D), and decreased maximum LV
pressure (Figure 3C), as well as the + dp/dt and –dp/dt
Figure 1 Characterization of mesenchymal stem cells and expression of pigment epithelium-derived factor. (A) Mesenchymal stem cells
(passage 3) from both young and older donor mice display fibroblast-like morphology in culture. In vitro adipocyte differentiation was confirmed
by Oil Red O staining (arrows show accumulation of lipid droplets in vacuoles). In vitro osteogenic differentiation was demonstrated by alizarin
red staining, demonstrating Ca2+ deposition (arrows). (B) Reverse transcriptase–polymerized chain reaction results demonstrated pigment
epithelium-derived factor mRNA levels in older mesenchymal stem cells and young mesenchymal stem cells under both normoxic/hypoxic
conditions (n ¼ 5 mice/group). (C ) Enzyme-linked immuno sorbent assay experiment demonstrated pigment epithelium-derived factor
protein levels in older mesenchymal stem cells and young mesenchymal stem cells culture supernatants (n ¼ 5 mice/group) Data expressed
as means+ SEM. *P, 0.01, **P, 0.001.
Figure 2 Localization of engrafted mesenchymal stem cells in the infarcted heart. (A) The representative image of infarcted heart 1 day post-
injection of adenoviral vector transduced mesenchymal stem cells (haematoxylin and eosin staining). (B) The fluorescent image of consecutive
sections of Figure 3A. Many green cells were dispersed in the infarct region. (C) Bar graph shows no significant differences (P ¼ 0.708) in the
green fluorescent intensity of infarcted hearts among Y&Ad.Null, Y&Ad.PEDF, O&Ad.shctrl, and O&Ad.shPEDF groups. Data expressed as means+
SEM (n ¼ 5 mice/group).
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(Figure 3E and F ), all data suggestive of decreased therapeutic
ability of old MSCs compared to young MSCs. Importantly, com-
pared with Y&Ad.Null cells, Y&Ad.PEDF not only significantly
increased LV fibrosis (Figure 3A), but also impaired LV function
(Figure 3B–F). In contrast, O&Ad.shPEDF decreased the LV fibrosis
area (Figure 3A), and ameliorated LV function compared with old
MSCs transduced with Ad.shctrl (Figure 3B–F), supporting the
notion that impaired therapeutic efficacy of old MSCs is associ-
ated with increased PEDF secretion.
Mesenchymal stem cells regulate the
cellular profile in the myocardial
infarction area via paracrine factor
pigment epithelium-derived factor
To investigate in the underlying mechanism contributing to age-
diminished efficacy against MI injury, we analysed the cellular
profile of the infarct region after administration of saline, young
MSCs, or old MSCs. In infarcted myocardial sample regions
Figure 3 Measurement of left ventricular fibrosis and function. (A) Representative Masson trichrome-stained myocardial sections and bar
graph showing fibrotic region measurement (n ¼ 5 mice/group). (B–E) Bar graphs illustrating left ventriculum function parameters (n ¼ 5
mice/group). Data expressed as means+ SEM. *P, 0.05, **P, 0.01, ***P ≤ 0.001. Pre-ejection period: left ventricular ejection time ratio,
the ratio of the pre-ejection period/left ventricular ejection time. Pmax, maximum pressure. Ped, end-diastolic pressure.
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7 days after MI, confocal microscopy images demonstrated signifi-
cantly increased density of vascular endothelial cells (ECs and
CD31-positive), vascular smooth muscle cells (VSMCs and aSMA-
positive), and macrophages (F4/80-positive) in mice having
received young or old MSCs compared to saline. In contrast,
fibroblast (vimentin-positive) density was significantly lower in
mice receiving young or old MSCs compared to saline
(Figures 4A and 5D). The infarct area of hearts subjected to old
MSCs contained significantly fewer ECs, VSMCs, and macro-
phages, but more fibroblasts compared to those subjected to
young MSCs (Figures 4A and 5D). To investigate whether the
differential cellular profile between young and old MSCs was
caused by variant PEDF level expression, we assessed the resul-
tant cellular profile following administration of genetically modi-
fied MSCs. Interestingly, we observed only a small proportion
of ECs, fibroblasts, VSMCs, and macrophages in the infarct
Figure 4 Mesenchymal stem cells alter the cellular profile in the myocardial infarction area through pigment epithelium-derived factor. (A–D)
Representative confocal microscopic images of CD31- or vimentin-, or aSMA- or F4/80-positive cells (red fluorescence, white arrows point to
representative positive cells) in infarct region 7 days after administration of saline, young mesenchymal stem cells, or older mesenchymal stem
cells (bar: 20 mm). Nuclei were stained by DAPI (blue fluorescence). The bar graph shows the cell density (n ¼ 5 mice/group). (E–H) Repre-
sentative confocal microscopic images of CD31- or vimentin- or aSMA- or F4/80-positive cells (red fluorescence) in infarct region 7 days after
administration of Y&Ad.Null, Y&Ad.PEDF, O&Ad.shctrl, or O&Ad.shPEDF groups (bar: 20 mm). Injected mesenchymal stem cells were green flu-
orescent protein-positive (green fluorescence). Nuclei were stained by DAPI (blue fluorescence). White arrows point to representative CD31-,
vimentin-, aSMA-, or F4/80 positive cells. Yellow arrows show representative CD31- or vimentin- or aSMA- or F4/80 and green fluorescent
protein double positive cells. Bar graph shows the cell density (n ¼ 5 mice/group). All data are expressed as means+ SEM. *P, 0.05,
**P, 0.01, ***P ≤ 0.001.
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Figure 5 Co-culture of cardiac fibroblasts with mesenchymal stem cells and the direct effects of pigment epithelium-derived factor on cardiac
fibroblasts. (A) Bar graph illustrates proliferation assays of cardiac fibroblasts co-cultured with mesenchymal stem cells. Cardiac fibroblasts
co-cultured with cardiac fibroblasts served as control. (B) Bar graph illustrates migration assays of cardiac fibroblasts co-cultured with mesench-
ymal stem cells. Cardiac fibroblasts co-cultured with cardiac fibroblasts served as control. (C) Bar graph shows the direct effect of pigment
epithelium-derived factor on cardiac fibroblasts proliferation. (D) Representative flow cytometry analyses for cell cycle and the bar graph
shows the effect of pigment epithelium-derived factor on cardiac fibroblasts’ cell cycle. (E) Representative western blotting analyses and bar
graphs demonstrate that pigment epithelium-derived factor regulated cardiac fibroblasts expression of cyclin D1 and P27. (F) The effect of
pigment epithelium-derived factor on cardiac fibroblasts apoptosis. Representative Hoechest stained images and bar graphs illustrating
degree of apoptosis for cardiac fibroblasts analysed by Hoechest staining or flow cytometry. White arrows show representative apoptotic
cells with nuclear fragmentation. (G) The effect of pigment epithelium-derived factor on cardiac fibroblast migration. Representative crystal
violet staining of migrated cardiac fibroblasts in the lower compartments of the transwell system and bar graph illustrating the effect of
pigment epithelium-derived factor on cardiac fibroblasts migration in transwell system. All data expressed as means+ SEM. n ¼ 6 per
group. *P, 0.05, **P, 0.01, ***P ≤ 0.001.
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region of hearts receiving CD31-, vimentin-, aSMA-, or F4/80-
cells (each with GFP double positivity, confirmatory of viral infec-
tivity, Figures 4E and 5H). Importantly, PEDF overexpression in
young MSCs (Y&Ad.PEDF group vs Y&Ad.Null group) not only
decreased the total number of ECs, VSMCs, and macrophages
(total CD31- or aSMA- or F4/80-positive cells), but also the
number of MSC-derived ECs, VSMCs, and macrophages in the
infarct region, whereas both fibroblast (all vimentin-positive
cells) and MSC-derived fibroblast populations were increased
(Figures 4E and 5H). Furthermore, knocking down PEDF
expression in old MSCs (O&Ad.shPEDF group vs. O&Ad.shctrl
group) increased the total number of ECs, VSMCs, and macro-
phages, as well as MSC-derived ECs, VSMCs, and macrophages
in the infarct region, whereas both fibroblast population and
MSC-derived fibroblast density was decreased (Figures 4E and
5H). These results suggest that MSCs can alter the cellular
profile within a MI area through PEDF paracrine factor, and fur-
thermore, this cellular profile alteration can be influenced by
the age-specific type PEDF expression present.
Pigment epithelium-derived factor
secreted by mesenchymal stem cells
stimulates cardiac fibroblast proliferation
and migration in dose dependent manner
It has been reported that PEDF can induce EC and macrophage
apoptosis, and inhibit the proliferation and migration of ECs and
VSMCs.11,15– 18 Our results demonstrating increased PEDF levels
in the infarct region associated with decreased ECs, VSMCs, and
macrophages are consistent with such reports. Additionally,
increased PEDF levels in the infarct region were associated with
increased fibroblast presence via an elusive underlying mechanism.
To provide further evidence that MSC-secreted PEDF can affect
fibroblast populations in the infarct region, we performed a trans-
well co-culture experiment with CFs and MSCs. We demonstrated
that CF proliferation was slower when they were cultured with
young MSCs than with old MSCs. Furthermore, this inhibitory
effect was markedly weaker when CFs were co-cultured with
Y&Ad.PEDF group (Figure 5A). Moreover, CF proliferation was
much slower when they were cultured with old MSCs after
PEDF expression had been knocked down (Figure 5A). In fact,
our data showed that PEDF protein alone stimulated CF prolifer-
ation under hypoxic conditions in a dose-dependent fashion
(Figure 5C). Pigment epithelium-derived factor (200 ng/mL) signifi-
cantly increased the number of CFs in S phase (Figure 5D),
up-regulated cyclin D1 expression, and down-regulated P27
(Figure 5E). However, 200 ng/mL PEDF did not have a pronounced
effect on CF apoptosis during hypoxia (Figure 5F). Additionally, we
demonstrated that either old MSCs with naturally high PEDF
expression, or young MSCs with overexpressed PEDF, attracted
more CFs in the transwell system. In contrast, knocking down
PEDF expression in old MSCs attenuated CF chemotaxis
(Figure 5B). Furthermore, by using PEDF protein to substitute
MSCs in the lower compartments of the transwell system, PEDF
alone was consistently shown to be an important chemoattractant
of the MSC secretome (Figure 5G).
Discussion
Mesenchymal stem cells isolated from adult bone marrow provide
excellent biomaterial source for therapeutic stem cell develop-
ment. Although the present findings and previous study demon-
strated MSCs could restore cardiac function partly via cell-type
differentiation potential after MI,19 the population contributions
of such cell differentiation subtypes were limited. Compelling evi-
dence has shown that the secretion of a broad range of bioactive
molecules by MSCs contributes to their cardiac repair role after
ischaemic onslaught.4 –6 In this study, we identified the paracrine
factor PEDF as a significant mediator of the resultant cellular
profile of the post-MI infarct region. Moreover, we demonstrated
that the decline in therapeutic efficacy of old MSCs was associated
with age-dependent paracrine PEDF release.
Encoded by a single gene, PEDF is a 50 kDa glycoprotein with
strong conservation across phyla from fish to mammals, and is
widely expressed among many tissues.11,15,16 Most secreted PEDF
deposit within the extracellular matrix, with cell-type-specific func-
tions.11,15,16 PEDF is known as a strong anti-angiogenic factor due
to its ability to induce EC apoptosis by activation of the Fas/Fas
ligand transduction cascade and p38 MAP kinas dependent cleavage
of caspases 3, 8, and 9, and is inhibitive of vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (bFGF)-induced EC
migration and proliferation.11,15,16 Conversely, it exerts anti-
apoptotic effects on neuronal or hepatoma cells by activating the
nuclear factor-kB signaling cascade or inhibiting lysosomal Bcl-xL
degradation, respectively.15,16,20 It can also inhibit platelet-derived
growth factor-induced VSMC proliferation and migration by block-
ing reactive oxygen species generation,18 although we recently
demonstrated that PEDF stimulated both proliferation and migration
of retinal pigment epithelial cells in a laser-induced choroidal neovas-
cularization model.21 It is speculated that the elusive functions of
PEDF may attribute to multiple unknown receptors, the immediate
cellular state, as well as pathologic signals and factors present in
the cellular microenvironment.16 Furthermore, age-related differen-
tial PEDF expression has been observed previously, but with incon-
sistent results among different tissues.22,23 We found presently that
PEDF expression in older mice MSCs was significantly greater than
from young mice. Notably, our results evidenced the negative corre-
lation between MSC-secreted PEDF quantity and therapeutic
potency against MI injury.
Angiogenesis is induced by MSC secretion of bioactive factors,
such as VEFG, bFGF, and hepatocyte growth factor, which
promote both EC and VSMC proliferation and migration.24 Con-
versely, MSCs also secrete PEDF, which can potentially induce
apoptosis, and inhibit EC and VSMC proliferation and migration
via above-mentioned mechanisms. Compared to young MSCs,
old MSCs secrete more PEDF in the infarct region. It is therefore
conceivable that increased PDEF levels exert more significant bio-
logical effects resulting in an infarct region containing fewer ECs
and VSMCs; hence, angiogenesis is inhibited. Moreover, CFs are
key effector cells in the pathogenesis of post-MI cardiac fibrosis,
and it has been shown that MSCs can attenuate CF proliferation
via a paracrine mechanism resulting in an anti-fibrotic effect.25
Our in vivo experimental results are confirmatory, demonstrating
both young and old MSCs administration, compared to saline,
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decreased fibroblast number and fibrotic region. Furthermore, the
anti-fibrotic effect of MSCs attenuated with age. Our results
suggested that this phenomenon was associated with the ability
of PEDF to stimulate CF proliferation. The underlying mechanism
likely involves up-regulation of cyclin D1 expression and P27
down-regulation, a cyclin-dependent kinase inhibitor arresting
G1. Consequently, an increased number of cells were in S phase,
whereas there was no effect upon apoptosis during hypoxia.
Additionally, we demonstrated PEDF stimulated CF chemotaxis
in dose-dependent fashion, as previously reported.9 Thus, our
study implies that, compared to younger MSCs, older MSCs
increased the fibroblast population in the infarct region at least
partly due to increased PEDF secretion. After MI, damaged cardi-
omyocytes are removed largely by macrophages and replaced by
scar tissue.2 In the present study, regardless of which cell type
received which genetic alteration of PEDF expression, the more
PEDF in the infarct region, the fewer macrophages were observed.
This phenomenon may be attributed to the findings of Ho et al.,17
which demonstrated that PEDF induces macrophage apoptosis and
necrosis via peroxisome proliferator-activated receptor g signaling.
In addition, PEDF can inhibit macrophage activation.26 Notably,
reduction in macrophage infiltration and decreased macrophage
activation are associated with significantly delayed MI healing, prin-
cipally due to deficient phagocytosis of injured cardiomyocytes and
delayed granulation tissue formation,27 yet another aetiology for
older MSCs’ decreased therapeutic efficacy.
The MSC delivery route having greatest impact on prevention of
remodelling post-MI has not been determined.28 In the current
study, we utilized peripheral venous injection of MSCs post-MI
for the following reasons. Firstly, MSCs can be infused intrave-
nously due to their ability to gravitate to injured regions within
the myocardium, stimulated, at least in part, by stromal cell-derived
factor-1/CXCR4 axis.29,30 Secondly, intravenous infusion remains
one of the safe, convenient, clinically relevant delivery approaches
in patients.31 Thirdly, it has been reported that the plastic
adherent-derived MSCs are not a homogeneous cell population,
which might be contaminated by a fibroblasts, osteoblasts, and adi-
pocytes.4 We speculate that these cellular contaminants (which
exhibit no chemotactic properties) are filtered out by the periph-
eral circulation. Lastly, we endeavored to assess the possible
impact of PEDF on MSC chemotaxis. Our results revealed the
rapid recruitment of MSCs to the MI area. Additionally, no signifi-
cant difference between groups was demonstrated in the relative
fluorescent intensity of the infarcted heart after infusion of
GFP-labeled MSCs, suggesting that PEDF has no significant
impact upon MSC chemotaxis. However, there is still a huge gap
between small animal models and practical clinical application,
and acknowledge the limitations of this current study that do not
address several major problems of stem cell-based therapy, includ-
ing targeted and effective MSCs delivery route, the most appropri-
ate time point for cell transplantation, and other risk control issues.
Overall, the current study confirmed that MSCs can regulate MI
pathological processes through paracrine actions. Thus, MSCs
could be considered an “organizer” in the MI area, manipulating
tissue cellular profile by secreting various growth factors and cyto-
kines. We demonstrated that PEDF was one of the most important
Figure 6 Schematic illustrating mesenchymal stem cells can regulate the cellular profile in the myocardial infarction area via paracrine factor
pigment epithelium-derived factor. Older mesenchymal stem cells express and secrete more pigment epithelium-derived factor in infarct region
than young mesenchymal stem cells, leading to fewer endothelial cells, vascular smooth muscle cells, and macrophages, but more fibroblasts in
the infarct region after older mesenchymal stem cell administration. (Biological effects of pigment epithelium-derived factor upon endothelial
cells, vascular smooth muscle cells, macrophages, and fibroblasts mentioned in schematic are based on present study results and previous
literatures).
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factors involved in MSC paracrine function. Pigment epithelium-
derived factor secreted by MSCs can act upon several cell
types in the infarct region (Figure 6). However, our experiments
were not designed to address all discrepancies in the paracrine
profile between young and older MSCs. Further experiments
defining the exact alteration of the aged MSCs paracrine profile
are clearly necessary. One method for increasing injury repair effi-
ciency, and minimizing undesirable outcomes, would be directly
manipulating the cell types controlling the pathological processes
at work.32 Therefore, our results imply that the most efficacious
aged-donor MSC utilization must focus upon optimizing paracrine
profile to favorably manipulate the cellular profile in the infarct
region. For such means, our study supports PEDF as a promising
novel genetic modification target for augmenting aged MSC
therapeutic efficacy.
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